查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600974

吸入和鼻噴霧的學名藥市場：按適應症、年齡層、藥物類別、路線和分銷管道 - 2025-2030 年全球預測

Inhalation & Nasal Sprays Generic Drugs Market by Indication (Allergic Rhinitis, Asthma, COPD), Age Group (Adults, Children 2 to 5, Children 6 to 12), Class, Route, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年吸入器和鼻噴霧的學名藥市值為80.9億美元，預計2024年將達到87.8億美元，複合年成長率為8.61%，到2030年將達到14.4億美元，預計將達到3000萬美元。

學名藥藥吸入器和鼻噴霧市場範圍涵蓋主要用於氣喘、慢性阻塞性肺病和過敏性鼻炎等呼吸系統疾病的頻譜藥物。這些學名藥為品牌藥提供了具有成本效益的替代品，並擴大了獲得基本治療方法的機會。對學名藥的需求源於世界各地呼吸系統疾病和過敏的日益流行，學名藥主要用於醫院、診所和居家醫療機構。最終用途範圍跨越年齡層，針對兒童和成人。影響成長的因素包括慢性呼吸道疾病盛行率上升、政府推廣學名藥使用的努力以及控制醫療費用的措施。此外，幾種重磅吸入藥物的專利已經到期，為學名藥​​製造商創造了利潤豐厚的商機。擴大我們的地理覆蓋範圍存在潛在的機會，特別是在對具有成本效益的醫療保健解決方案的需求不斷增加的新興市場。簡化您的監管核准流程並加強您的分銷網路，以進一步增強您的市場影響力。然而，市場成長面臨嚴格的監管障礙、領先公司之間的激烈競爭以及學名藥與品牌藥相比生物等效性的潛在問題等挑戰。有限的製造能力以及需要高額研發投資以實現治療等效性和設備創新也是主要障礙。在創新方面，先進藥物輸送系統的開發存在成長機會，例如可以提高依從性並提供即時使用資料的數位吸入器。潛在的研究領域包括研究個人化醫療、針對特定患者群體最佳化配方以及專注於吸入器的環保推進劑。市場是充滿活力和競爭的，不斷進步增加了策略創新和適應的需求，以有效佔領市場佔有率。

主要市場統計
基準年[2023] 80.9億美元
預測年份 [2024] 87.8億美元
預測年份 [2030] 144.3億美元
複合年成長率（%） 8.61%

市場動態：吸入器和鼻噴霧快速發展的學名藥市場的關鍵市場洞察

供需的動態交互作用正在改變吸入器和鼻噴霧的學名藥市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 學名藥非專利藥的成本較低
    • 呼吸道疾病盛行率增加
    • 兒科霧化器的顯著普及
  • 市場限制因素
    • 對學名藥的嚴格監管
  • 市場機會
    • 重磅藥物專利到期和 FDA核准增加
    • 藥廠加大研發投入
  • 市場挑戰
    • 由於該細分市場存在多個參與者而造成價格壓力

波特五力：開拓吸入器和鼻噴霧學名藥市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對吸入器和鼻噴霧學名藥市場的影響

外部宏觀環境因素在塑造學名藥藥吸入和鼻噴霧市場的業績動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解吸入器和鼻噴霧學名藥市場的競爭狀況

對學名藥吸入和鼻噴霧市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位基質吸入和鼻噴霧學名藥市場供應商績效評估

FPNV定位矩陣是評估學名藥藥吸入和鼻噴霧市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。四個象限清楚且準確地分類了供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 學名藥成本低
      • 呼吸道疾病盛行率增加
      • 兒科霧化器重要介紹
    • 抑制因素
      • 對學名藥的嚴格監管
    • 機會
      • 重磅藥物專利到期和 FDA核准數量增加
      • 藥廠加大研發投入
    • 任務
      • 多個參與者的存在增加了價格壓力
  • 市場區隔分析
    • 適應症：需要使用治療過敏性鼻炎的學名藥快速、即時緩解症狀
    • 年齡層：加強2~5歲兒童產品研發
    • 分銷管道：網路藥局變得越來越受歡迎，因為它們提供有競爭力的價格和便利性。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化
    • 處方和給藥裝置的變更

第6章 吸入器和鼻噴霧的適應症學名藥市場

  • 過敏性鼻炎
  • 氣喘
  • 慢性阻塞性肺病

第7章 吸入器和鼻噴霧的學名藥市場：按年齡層

  • 成人
  • 2歲至5歲兒童
  • 6至12歲兒童

第8章吸入器和鼻噴霧的學名藥市場：按類別

  • 過敏阻斷劑
  • 抗膽鹼能藥
  • 抗組織胺藥
  • 減充血劑
  • 肥大細胞抑制劑
  • 鼻類固醇

第9章 吸入器和鼻噴霧的學名藥市場：按途徑

  • 吸入
  • 鼻噴劑
  • 熱帶乳液

第10章吸入器和鼻噴霧的學名藥市場：按配銷通路

  • 醫院醫療用品店
  • 網路藥房
  • 藥局零售業

第11章 美洲吸入器和鼻噴霧的學名藥市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章 亞太地區吸入器和鼻噴霧學名藥市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲吸入器和鼻噴霧學名藥市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Usea Pharma非專利Budesonide獲得美國FDA核准
    • Amphastar Pharmaceuticals 的鹽酸納洛酮鼻滴鼻劑4 毫克獲得 FDA核准
    • Amneal 宣布其鹽酸納洛酮滴鼻劑（USP，4mg）的簡化新藥申請已被美國FDA 受理

公司名單

  • Chiesi Farmaceutici SpA
  • Altaire Pharmaceuticals Inc.
  • Apotex Inc.
  • Amphastar Pharmaceuticals, Inc.
  • Hikma Pharmaceuticals PLC
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Limited
  • AstraZeneca PLC
  • Sandoz International GmbH
  • Viatris Inc.
  • AbbVie Inc.
  • Nephron Pharmaceuticals Corporation
  • Zhejiang Xianju Pharmaceutical Co., Ltd.
  • Preferred Pharmaceuticals, Inc.
  • Acerus Pharmaceuticals Corporation
  • Mylan NV
  • Beximco Pharmaceuticals Ltd.
  • Akorn, Inc.
  • Perrigo Company PLC
  • GlaxoSmithKline PLC
  • Nippon Shinyaku Co., Ltd.
  • Sanofi SA
  • Padagis US LLC
  • AptarGroup, Inc.
  • Recipharm AB
  • Teva Pharmaceutical Industries Ltd.
  • Catalent, Inc.
Product Code: MRR-032A67D9141A

The Inhalation & Nasal Sprays Generic Drugs Market was valued at USD 8.09 billion in 2023, expected to reach USD 8.78 billion in 2024, and is projected to grow at a CAGR of 8.61%, to USD 14.43 billion by 2030.

The scope of the inhalation and nasal sprays generic drugs market encompasses a wide spectrum of medications used primarily for respiratory conditions such as asthma, COPD, and allergic rhinitis. These generic drugs offer cost-effective alternatives to branded medications, expanding access to essential therapies. Necessity for these drugs arises from the increasing prevalence of respiratory diseases and allergies worldwide, fueling their application primarily in hospitals, clinics, and homecare settings. End-use scope spans across age groups, catering to both pediatric and adult populations. Influencing growth factors include the rising incidence of chronic respiratory ailments, government initiatives to promote generic drug usage, and healthcare cost containment measures. Additionally, the expiration of patents for several blockbuster inhalation drugs opens lucrative opportunities for generics manufacturers. Potential opportunities lie in expanding geographical reach, particularly in emerging markets where demand for cost-effective healthcare solutions is mounting. Streamlining the regulatory approval process and enhancing distribution networks can further solidify market presence. Yet, market growth faces challenges such as stringent regulatory hurdles, high competition among leading players, and potential issues related to the bioequivalence of generics compared to brand-name counterparts. Limitations in manufacturing capabilities and the necessity for high investment in R&D to achieve therapeutic equivalence and device innovation are also significant barriers. On the innovation front, opportunities for growth lie in the development of advanced drug-delivery systems, such as digital inhalers that improve adherence and provide real-time usage data. Research into personalized medicine, optimizing formulations to target specific patient demographics, and focusing on eco-friendly propellants in inhalers are other potential areas of exploration. The market is dynamic and competitive, with continuous advancements fostering a need for strategic innovation and adaptation to capture market share effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 8.09 billion
Estimated Year [2024] USD 8.78 billion
Forecast Year [2030] USD 14.43 billion
CAGR (%) 8.61%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Inhalation & Nasal Sprays Generic Drugs Market

The Inhalation & Nasal Sprays Generic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Low Cost Involved with Generic Prescription Drugs
    • Increasing Prevalence of Respiratory Diseases
    • Significant Adoption of Nebulizers for Children
  • Market Restraints
    • Stringent Regulations For Generic Drugs
  • Market Opportunities
    • Patent Expiry of Blockbuster Drugs and Increasing FDA Approvals
    • Growing Investments from Pharmaceutical Companies for R&D
  • Market Challenges
    • Pricing Pressure due to Presence of Multiple Players in the Segment

Porter's Five Forces: A Strategic Tool for Navigating the Inhalation & Nasal Sprays Generic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Inhalation & Nasal Sprays Generic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Inhalation & Nasal Sprays Generic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Inhalation & Nasal Sprays Generic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Inhalation & Nasal Sprays Generic Drugs Market

A detailed market share analysis in the Inhalation & Nasal Sprays Generic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Inhalation & Nasal Sprays Generic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Inhalation & Nasal Sprays Generic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Inhalation & Nasal Sprays Generic Drugs Market, highlighting leading vendors and their innovative profiles. These include Chiesi Farmaceutici S.p.A., Altaire Pharmaceuticals Inc., Apotex Inc., Amphastar Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Cipla Limited, AstraZeneca PLC, Sandoz International GmbH, Viatris Inc., AbbVie Inc., Nephron Pharmaceuticals Corporation, Zhejiang Xianju Pharmaceutical Co., Ltd., Preferred Pharmaceuticals, Inc., Acerus Pharmaceuticals Corporation, Mylan N.V., Beximco Pharmaceuticals Ltd., Akorn, Inc., Perrigo Company PLC, GlaxoSmithKline PLC, Nippon Shinyaku Co., Ltd., Sanofi S.A., Padagis US LLC, AptarGroup, Inc., Recipharm AB, Teva Pharmaceutical Industries Ltd., and Catalent, Inc..

Market Segmentation & Coverage

This research report categorizes the Inhalation & Nasal Sprays Generic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Allergic Rhinitis, Asthma, and COPD.
  • Based on Age Group, market is studied across Adults, Children 2 to 5, and Children 6 to 12.
  • Based on Class, market is studied across Allergy Blocker, Anticholinergic, Antihistamine, Decongestant, Mast Cell Inhibitor, and Nasal Steroid.
  • Based on Route, market is studied across Inhalation, Nasal Spray, and Tropical Lotion.
  • Based on Distribution Channel, market is studied across Hospital Medical Store, Online Pharmacy, and Pharmacy Retail.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Low Cost Involved with Generic Prescription Drugs
      • 5.1.1.2. Increasing Prevalence of Respiratory Diseases
      • 5.1.1.3. Significant Adoption of Nebulizers for Children
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent Regulations For Generic Drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Patent Expiry of Blockbuster Drugs and Increasing FDA Approvals
      • 5.1.3.2. Growing Investments from Pharmaceutical Companies for R&D
    • 5.1.4. Challenges
      • 5.1.4.1. Pricing Pressure due to Presence of Multiple Players in the Segment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Indication: Need for quick and immediate symptom relief generic medications for allergic rhinitis
    • 5.2.2. Age Group: Increasing product development for children aged 2 to 5
    • 5.2.3. Distribution Channel: Growing popularity of online pharmacies offering competitive pricing and convenience
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization
    • 5.5.1. Changing Formulation & Delivery Device

6. Inhalation & Nasal Sprays Generic Drugs Market, by Indication

  • 6.1. Introduction
  • 6.2. Allergic Rhinitis
  • 6.3. Asthma
  • 6.4. COPD

7. Inhalation & Nasal Sprays Generic Drugs Market, by Age Group

  • 7.1. Introduction
  • 7.2. Adults
  • 7.3. Children 2 to 5
  • 7.4. Children 6 to 12

8. Inhalation & Nasal Sprays Generic Drugs Market, by Class

  • 8.1. Introduction
  • 8.2. Allergy Blocker
  • 8.3. Anticholinergic
  • 8.4. Antihistamine
  • 8.5. Decongestant
  • 8.6. Mast Cell Inhibitor
  • 8.7. Nasal Steroid

9. Inhalation & Nasal Sprays Generic Drugs Market, by Route

  • 9.1. Introduction
  • 9.2. Inhalation
  • 9.3. Nasal Spray
  • 9.4. Tropical Lotion

10. Inhalation & Nasal Sprays Generic Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Medical Store
  • 10.3. Online Pharmacy
  • 10.4. Pharmacy Retail

11. Americas Inhalation & Nasal Sprays Generic Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Inhalation & Nasal Sprays Generic Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Inhalation & Nasal Sprays Generic Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Eugia Pharma Gets USFDA Nod for Budesonide Generic
    • 14.3.2. Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg
    • 14.3.3. Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg

Companies Mentioned

  • 1. Chiesi Farmaceutici S.p.A.
  • 2. Altaire Pharmaceuticals Inc.
  • 3. Apotex Inc.
  • 4. Amphastar Pharmaceuticals, Inc.
  • 5. Hikma Pharmaceuticals PLC
  • 6. Sun Pharmaceutical Industries Ltd.
  • 7. Cipla Limited
  • 8. AstraZeneca PLC
  • 9. Sandoz International GmbH
  • 10. Viatris Inc.
  • 11. AbbVie Inc.
  • 12. Nephron Pharmaceuticals Corporation
  • 13. Zhejiang Xianju Pharmaceutical Co., Ltd.
  • 14. Preferred Pharmaceuticals, Inc.
  • 15. Acerus Pharmaceuticals Corporation
  • 16. Mylan N.V.
  • 17. Beximco Pharmaceuticals Ltd.
  • 18. Akorn, Inc.
  • 19. Perrigo Company PLC
  • 20. GlaxoSmithKline PLC
  • 21. Nippon Shinyaku Co., Ltd.
  • 22. Sanofi S.A.
  • 23. Padagis US LLC
  • 24. AptarGroup, Inc.
  • 25. Recipharm AB
  • 26. Teva Pharmaceutical Industries Ltd.
  • 27. Catalent, Inc.

LIST OF FIGURES

  • FIGURE 1. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COPD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CHILDREN 2 TO 5, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CHILDREN 6 TO 12, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ALLERGY BLOCKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DECONGESTANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY MAST CELL INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY NASAL STEROID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY TROPICAL LOTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY HOSPITAL MEDICAL STORE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PHARMACY RETAIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 239. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 240. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023